Loading publications…
The last 5 uploaded publications
Association of early PSMA upregulation with duration of response to enzalutamide with or without [177Lu]Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901)
Louise Emmett, Mina Swiha, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua, Andrew Nguyen, Andrew Weickhardt, Sze Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Sarennya Pathmanandavel, Narjess Ayati, Michael S. Hofman, Shahneen Sandhu, Andrew Martin, Hayley Thomas, Martin R. Stockler, Ian D. Davis (2025). Association of early PSMA upregulation with duration of response to enzalutamide with or without [177Lu]Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901). , DOI: https://doi.org/10.21203/rs.3.rs-6307229/v1.
Preprint62 days agoPredictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ <sup>177</sup> Lu] Lu-PSMA-617 (ANZUP1901).
Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua, Andrew Nguyen, Andrew Weickhardt, Sze Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Michael S. Hofman, Shahneen Sandhu, Andrew Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler (2025). Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ <sup>177</sup> Lu] Lu-PSMA-617 (ANZUP1901).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5011.
Article62 days agoLutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Edmond M. Kwan, Sarah W.S. Ng, Sofie H. Tolmeijer, Louise Emmett, Shahneen Sandhu, James Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Vijay Subhash, Sze-Ting Lee, Andrew M. Scott, Andrew Martin, Martin R. Stockler, Gráinne Donnellan, Matti Annala, Cameron Herberts, Ian D. Davis, Michael S. Hofman, Arun Azad, Alexander W. Wyatt (2025). Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. , DOI: https://doi.org/10.1038/s41591-025-03704-9.
Article62 days agoClonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving <sup>177</sup> Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).
Aslı D. Munzur, Cameron Herberts, Edmond M. Kwan, Louise Emmett, Shahneen Sandhu, James Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Sze Ting Lee, Andrew M. Scott, Andrew Martin, Martin R. Stockler, Alison Yan Zhang, Scott Williams, Jack V. W. Bacon, Arun Azad, Ian D. Davis, Michael S. Hofman, Alexander W. Wyatt (2025). Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving <sup>177</sup> Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5020.
Article62 days agoOverall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua, Shahneen Sandhu, Andrew Nguyen, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Craig Gedye, Natalie Rutherford, Aravind S. Ravi Kumar, David Pook, Shakher Ramdave, David Nadebaum, Mark Voskoboynik, Andrew D. Redfern, W A Macdonald, Laurence E. Krieger, Geoffrey Schembri, Wei Chua, Peter Lin, Lisa G. Horvath, Patricia Bastick, Patrick Butler, Alison Yan Zhang, Margaret McJannett, Hayley Thomas, Ailsa Langford, Michael S. Hofman, Andrew Martin, Ian D. Davis, Martin R. Stockler (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. , DOI: https://doi.org/10.1016/s1470-2045(25)00009-9.
Article62 days ago